The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Observational cohort study focused on treatment continuity of patients (pts) treated with XELOX plus bevacizumab (BV) for previously untreated metastatic colorectal cancer (mCRC).
Masahito Kotaka
Honoraria - Chugai Pharma
Husao Ikeda
No relevant relationships to disclose
Taro Ikumoto
No relevant relationships to disclose
Masaki Tsuzie
No relevant relationships to disclose
Shinichi Yoshioka
No relevant relationships to disclose
Yoshihiko Nakamoto
No relevant relationships to disclose
Takaaki Ishii
No relevant relationships to disclose
Saori Goto
No relevant relationships to disclose
Atsushi Itami
No relevant relationships to disclose
Takeshi Kato
No relevant relationships to disclose